newsfilter
← Latest News
GlobeNewswire·

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

SAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based